Nrf1 is Paved As a New Strategic Avenue to Prevent and Treat Cancer, Neurodegenerative and Other Diseases
Overview
Toxicology
Authors
Affiliations
Transcription factor Nrf1 acts as a unique vital player in maintaining cellular homeostasis and organ integrity during normal development and growth throughout the life process. Loss-of-function of Nrf1 results in severe oxidative stress, genomic instability, embryonic lethality, developmental disorders, and adult diseases such as non-alcoholic steatohepatitis, hepatocellular carcinoma, diabetes and neurogenerative diseases. Thereby, Nrf1 is critically implicated in a variety of important physio-pathological processes by governing robust target genes in order to reinforce antioxidant, detoxification and cytoprotective responses to cellular stress. Notably, there also exists a proteasomal 'bounce-back' response mediated by Nrf1, insofar as to enhance the drug resistance to proteasomal inhibitors in clinical treatment of neuroblastoma, multiple myeloma and triple-negative breast cancers. Recently, several drugs or chemicals are found or re-found in new ways to block the proteasomal compensatory process through inhibiting the multistep processing of Nrf1. Conversely, activation of Nrf1 induced by some drugs or chemicals leads to cytoprotection from cell apoptosis and promotes cell viability. This is the start of constructive and meaningful studies, approaching to explore the mechanism(s) by which Nrf1 is activated to protect neurons and other cells from malignant and degenerative diseases. Overall, Nrf1 has appealed attentions as a new attractive therapeutic strategy for human diseases including cancers.
New insight into the CNC-bZIP member, NFE2L3, in human diseases.
Xiong G, Li J, Yao F, Yang F, Xiang Y Front Cell Dev Biol. 2024; 12:1430486.
PMID: 39149514 PMC: 11325725. DOI: 10.3389/fcell.2024.1430486.
Knockdown of CPSF4 Inhibits Bladder Cancer Cell Growth by Upregulating NRF1.
Sun Y, Li G, Zhang H, Xie M Biochem Genet. 2024; .
PMID: 39039322 DOI: 10.1007/s10528-024-10891-6.
Liu L, Yin P, Yang R, Zhang G, Wu C, Zheng Y Front Immunol. 2024; 15:1351908.
PMID: 38863714 PMC: 11165063. DOI: 10.3389/fimmu.2024.1351908.
Liu K, Hu S, Qiu L, Wang M, Zhang Z, Sun G PLoS One. 2023; 18(11):e0294508.
PMID: 38011090 PMC: 10681226. DOI: 10.1371/journal.pone.0294508.
Chen W, Hu Q, Hou W, Chen M, Chen Y, Tang J Oncol Lett. 2023; 26(4):443.
PMID: 37720674 PMC: 10502936. DOI: 10.3892/ol.2023.14030.